Ludwig Enterprises Begins PCR Validation Test Process
Ludwig Enterprises (OTC PINK:LUDG) has initiated the PCR validation test process for its breast cancer screening program, Revealia™. The company has engaged an independent Florida laboratory for third-party validation of their PCR-based screening technology. The validation process, typically taking 6-8 weeks, is being expedited to 5-6 weeks, targeting a Q4 2024 launch. The screening panel utilizes PCR evaluation of 6 mRNA biomarkers to enhance sensitivity and predictability in breast cancer detection.
Ludwig Enterprises (OTC PINK:LUDG) ha avviato il processo di test di validazione PCR per il suo programma di screening del cancro al seno, Revealia™. L'azienda ha coinvolto un laboratorio indipendente della Florida per la validazione di terze parti della loro tecnologia di screening basata su PCR. Il processo di validazione, che solitamente richiede 6-8 settimane, è stato accelerato a 5-6 settimane, con l'obiettivo di un lancio nel quarto trimestre del 2024. Il pannello di screening utilizza la valutazione PCR di 6 biomarcatori mRNA per migliorare la sensibilità e la prevedibilità nella rilevazione del cancro al seno.
Ludwig Enterprises (OTC PINK:LUDG) ha iniciado el proceso de prueba de validación de PCR para su programa de detección de cáncer de mama, Revealia™. La empresa ha contratado a un laboratorio independiente en Florida para la validación de terceros de su tecnología de detección basada en PCR. El proceso de validación, que normalmente toma de 6 a 8 semanas, se está acelerando a 5-6 semanas, con el objetivo de un lanzamiento en el cuarto trimestre de 2024. El panel de detección utiliza la evaluación de PCR de 6 biomarcadores de ARNm para mejorar la sensibilidad y la predictibilidad en la detección del cáncer de mama.
루드윅 기업(Ludwig Enterprises, OTC PINK:LUDG)은 유방암 스크리닝 프로그램인 Revealia™의 PCR 유효성 검사 프로세스를 시작했습니다. 회사는 PCR 기반 스크리닝 기술에 대한 제3자 검증을 위해 플로리다에 있는 독립적인 실험실과 협력하고 있습니다. 일반적으로 6-8주가 소요되는 유효성 검사 과정은 5-6주로 단축되고 있으며, 2024년 4분기 출시를 목표로 하고 있습니다. 스크리닝 패널은 6개의 mRNA 바이오마커에 대한 PCR 평가를 활용하여 유방암 감지의 민감성과 예측 가능성을 높입니다.
Ludwig Enterprises (OTC PINK:LUDG) a lancé le processus de test de validation PCR pour son programme de dépistage du cancer du sein, Revealia™. L'entreprise a engagé un laboratoire indépendant en Floride pour la validation par un tiers de sa technologie de dépistage basée sur la PCR. Le processus de validation, qui prend normalement 6 à 8 semaines, est accéléré à 5-6 semaines, avec un lancement prévu pour le quatrième trimestre 2024. Le panneau de dépistage utilise l'évaluation PCR de 6 biomarqueurs d'ARNm pour améliorer la sensibilité et la prévisibilité dans la détection du cancer du sein.
Ludwig Enterprises (OTC PINK:LUDG) hat den PCR-Validierungstestprozess für sein Brustkrebsscreening-Programm Revealia™ eingeleitet. Das Unternehmen hat ein unabhängiges Labor in Florida beauftragt, um die Validierung ihrer PCR-basierten Screening-Technologie durch Dritte durchzuführen. Der Validierungsprozess, der normalerweise 6-8 Wochen dauert, wird auf 5-6 Wochen beschleunigt, mit dem Ziel, im vierten Quartal 2024 auf den Markt zu kommen. Das Screening-Panel nutzt die PCR-Bewertung von 6 mRNA-Biomarkern, um die Sensibilität und Vorhersagbarkeit bei der Brustkrebserkennung zu verbessern.
- Approaching final stage before nationwide product launch
- Accelerated validation timeline from 6-8 weeks to 5-6 weeks
- Enhanced screening panel with 6 mRNA biomarkers for improved sensitivity
- Product launch dependent on successful validation results
- Timeline constraints for Q4 2024 launch may pose execution risks
Final step before the full launch of breast cancer screening program, Revealia™
SPARKS, NV / ACCESSWIRE / November 7, 2024 / Ludwig Enterprises, Inc. (OTC PINK:LUDG), a leading USA-based biotechnology company (the "Company"), has retained an independent lab in Florida that will conduct a third-party validation process for the Company's PCR (Polymerase Chain Reaction) breast cancer screening program, Revealia™. Once the validation protocols have been established and testing completed, Revealia™ will begin its nationwide launch.
Assay optimization and validation are essential, even when using assays that have been predesigned and commercially obtained. Optimization is required to ensure that the assay is as sensitive as required and specific to the target of interest. This process ensures that they are sensitive enough to detect indications of rare diseases or specific biomarkers and identify the relevant targets. Assay conditions must be optimized to detect all targets - universally. Validation provides the data required to justify the continued use of the assay in further research projects.
The validation process often takes 6-8 weeks to finalize, but the Company will work with the contracted lab to achieve a reduced timeline of 5-6 weeks, potentially allowing for a launch of Revealia™ in the 4th quarter of 2024.
"We are very excited to begin this final leg towards the launch of Revealia™. We have increased the sensitivity and predictability of the screening panel by using PCR evaluation of 6 mRNA biomarkers," stated Marvin S. Hausman MD, CSO of the Company. "Our innovative and non-invasive screening test empowers people to be proactive with their medical care and potentially detect health issues early on."
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. (which is to change its name to Revealia, Inc.), a biotech and healthcare holding company, is a global - innovator in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor, and create solutions to -mitigate chronic inflammation, the causative agent of illnesses such as cancer and heart disease, which are responsible for more than
For more information, please visit: http://www.ludwigent.com
About Revealia™
Revealia™ is a breast cancer screening test that utilizes a proprietary mRNA microarray to establish a personalized inflammatory index that provides a patient with reliable information that can assist in their healthcare medical decisions. - Artificial intelligence (AI) is used to determine a risk score, which is derived from a specific array of inflammatory biomarkers and comparing it to a database of previously analyzed patients.
For more information, please visit: www.revealia.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises, Inc.
www.ludwigent.com
Twitter: @LUDG_inc
Investor Relations
Resources Unlimited NW LLC
Mike Sheikh, Investor Relations
mike@resourcesunlimtedllc.com
Contact Information
Mike Sheikh
Investor Relations
mike@resourcesunlimtedllc.com
SOURCE: Ludwig Enterprise, Inc.
View the original press release on accesswire.com
FAQ
When will Ludwig Enterprises (LUDG) launch its Revealia breast cancer screening program?
What technology does Ludwig Enterprises (LUDG) use in its Revealia cancer screening?
How long will the PCR validation process take for Ludwig Enterprises (LUDG) Revealia?
